All In Biotech

Drug Trial Radar · NCT05181085

Study of NST-6179 in Healthy Subjects

A Phase 1, First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST 6179 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

70

Actual

Start

Nov 11, 2021

Primary completion

May 27, 2022

Study completion May 27, 2022

Sponsor

Lead sponsor
NorthSea Therapeutics B.V.Industry
Sponsor type
Industry
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.

Conditions

  • Short Bowel Syndrome
  • Parenteral Nutrition Associated Liver Disease

Interventions

  • NST 6179Drug

    orally administered, fully synthetic medium chain fatty acid (MCFA) analogue

  • PlaceboDrug

    inactive analogue

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With AEs and SAEs Following Administration of NST 6179Time frame: From screening to 14 days post final dose, up to 4 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit, Ltd

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.